Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics

23 Jun, 2016, 08:20 ET from Chelmsford Park SA

NEW YORK, June 23, 2016 /PRNewswire/ --

On Wednesday, June 22, 2016, the NASDAQ Composite ended the trading session at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% lower to finish at 17,780.83; and the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Nektar Therapeutics (NASDAQ: NKTR), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and BIND Therapeutics Inc. (NASDAQ: BIND). Learn more about these stocks by accessing their free trade alerts at:

http://stock-callers.com/registration

Infinity Pharmaceuticals Inc., a drug discovery and development Company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. The stock closed the day flat at $1.32 with a total volume of 2.23 million shares traded. The stock is trading 73.52% below its 50-day moving average. Additionally, Infinity Pharmaceuticals' stock has a Relative Strength Index (RSI) of 16.11. Sign up and read the free notes on INFI at:

http://stock-callers.com/registration/?symbol=INFI

On Wednesday, shares in Nektar Therapeutics which develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the U.S., ended the day 0.73% higher at $15.09 with a total volume of 602,636 shares traded. The Company's shares have advanced 7.25% in the last one month, 19.76% in the previous three months and 20.05% in the past one year. The stock is trading above its 50-day and 200-day moving averages by 0.73% and 10.41%, respectively. Furthermore, shares of Nektar Therapeutics have an RSI of 47.00. The complimentary notes on NKTR can be downloaded in PDF format at:

http://stock-callers.com/registration/?symbol=NKTR

Milton, Canada headquartered specialty pharmaceutical Company, Aralez Pharmaceuticals Inc.'s stock finished Wednesday's session 1.52% higher at $3.34 with a total volume of 500,697 shares traded. The stock is trading below its 50-day moving average by 12.34%. Aralez Pharmaceuticals' stock has an RSI of 29.46. Register for free on Stock-Callers.com and access the latest research on ARLZ at:

http://stock-callers.com/registration/?symbol=ARLZ

On Wednesday, shares in Cambridge, Massachusetts headquartered biotechnology Company, BIND Therapeutics Inc., ended the session 5.94% lower at $0.41 with a total volume of 184,154 shares traded. The stock is trading 43.32% below its 50-day moving average. Moreover, shares of BIND Therapeutics have an RSI of 32.85. Get free access to your trade alert on BIND at:

http://stock-callers.com/registration/?symbol=BIND

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA